-
2023-507220-23-00
5
2024-07-26
Transthyretin Amyloidosis with Cardiomyopathy
-
2025-521480-12-00
1
2025-10-22
Advanced solid tumors, Breast Cancer
-
2023-507905-33-00
1
2025-09-30
Advanced solid tumors
-
2025-521029-34-00
4
2025-09-18
Patients with overt hepatic encephalopathy (OHE) and acute decompensat
-
2025-521451-23-00
5
2025-09-03
Subjects scheduled for elective colonoscopy performed according to ESG
-
2024-513440-29-00
10
2025-06-25
Sickle cell disease vaso-occlusive crisis
-
2023-506545-27-01
4
2025-01-28
Diabetes mellitus, Type 1
-
2024-513529-21-00
6
2025-01-24
Lipedema
-
2024-511557-21-00
5
2024-11-14
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
-
2024-512848-30-00
4
2024-11-12
HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
-
2023-505433-27-00
5
2024-08-13
Atopic Dermatitis
-
2023-508736-62-00
4
2024-08-08
Heart failure (HF) with reduced ejection fraction (HFrEF)
-
2023-504564-42-00
4
2024-04-08
Moderate to Severe Rheumatoid Arthritis
-
2023-505900-53-00
4
2024-04-08
HIV infection
-
2023-509888-24-00
6
2024-04-08
Gastroscopy
-
2023-507125-41-00
9
2024-03-25
Advanced or Metastatic Breast Cancer
-
2022-500389-84-00
6
2024-02-16
Febrile neutropenia
-
2023-505543-39-00
5
2024-02-12
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-502529-17-00
5
2024-01-18
Obesity
-
2023-503614-80-00
5
2023-12-14
Pulmonary Arterial Hypertension
-
2024-512650-21-00
5
2023-12-13
Thyroid Eye Disease (TED)
-
2023-506250-20-00
5
2023-12-11
ulcerative pyoderma gangrenosum
-
2022-502540-12-00
5
2023-11-09
Refractory Status Epilepticus (RSE)
-
2023-503356-27-00
4
2023-09-07
Metastatic colorectal cancer that is resistant to the currently approv